China Biopharmaceuticals (01177): The CDK2/4/6 inhibitor Combinacil was publicly announced at ASCO in 2026 with Phase II clinical data in a treated population of CDK4/6 inhibitors.

Zhixin Finance APP, China Biopharmaceutical (01177) announced that its subsidiary Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing) independently developed a national class 1 innovative drug library Moxili "CDK2/4/6 inhibitor" (development code: TQB3616, trade name: Saitanxin) disclosed at the 2026 American Society of Clinical Oncology (ASCO) meeting a Phase II clinical research data in the CDK4/6 inhibitor (CDK4/6i) treated population. The results showed that the combination of Inhibitors achieved the pre-set primary endpoint, demonstrating encouraging antitumor activity and manageable safety, providing new options for targeted therapy for CDK4/6i-resistant patients.